Ascorbic acid plus immunotherapy for spread colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether intravenous vitamin C (ascorbic acid) combined with an immune treatment (adebrelimab) can slow or shrink metastatic colorectal cancer that can’t be removed with surgery. It focuses on tumors that strongly show a specific marker called GLUT3, and aims to see if the combination works better than standard approaches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 75 years old and have colorectal cancer that has spread to the lining of the abdomen (peritoneum) and cannot be removed by surgery
- Have biopsy-confirmed colorectal cancer and tumor tissue showing strong GLUT3 marker staining (not low or moderate)
- Have at least one measurable area of cancer, and be active enough for treatment (ECOG score 0 to 1)
- Have blood counts in safe ranges (ANC ≥ 1,500; hemoglobin > 8 g/dL; platelets ≥ 100,000)
- Your kidneys and liver tests must be acceptable for treatment (creatinine within limits or kidney clearance > 50 mL/min; certain AST/ALT and bilirubin limits)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether adding vitamin E to two cancer medicines (fruityquintinib and tislelizumab) can work better in people with metastatic colorectal cancer that is mismatch-repair stable (MSS). It may help if your cancer has grown despite standard treatment, and you can meet the study’s safety and blood/organ requirements.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
This study tests a new combination of drugs (an immunotherapy called QL1706 plus bevacizumab and standard chemotherapy) as a first-line treatment for people with advanced colorectal cancer that has a BRAF V600E mutation. The goal is to see if this combination helps shrink tumors and improve outcomes.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.